Home / Stocks / Akums Drugs And Pharma L
AKUMS

Akums Drugs And Pharma L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹712.85

Change

-3.3 (-0.46%)

Open

₹717.0

Prev. Close

₹716.15

Day High

₹717.05

Day Low

₹702.65

Volume Analysis

Traded

75,490

Delivered

42,069

Delivery %

55.73%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Low return on equity (8.45%)

Opportunities (1)

  • •Strong 3-year EPS growth (36.0%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹733.45 ₹725.25 ₹719.05 ₹710.85 ₹704.65 ₹696.45 ₹690.25
Fibonacci ₹725.25 ₹719.75 ₹716.35 ₹710.85 ₹705.35 ₹701.95 ₹696.45
Camarilla ₹716.81 ₹715.49 ₹714.17 ₹710.85 ₹711.53 ₹710.21 ₹708.89

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+59.87%

1 Week

-4.94%

1 Month

+2.71%

3 Months

-4.95%

6 Months

+37.07%

1 Year

+69.1%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹285.19

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

9.41%

Net margin 7.56% × asset turnover 0.75x × equity multiplier 1.66x

Company Overview

Sector

Healthcare

Market Cap

₹11,279 Cr

P/E (TTM)

29.9

ROE

8.45%

Book Value

₹223.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Akums Drugs And Pharma L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 67/100. The strongest factor is Financial Strength (100/100), while Institutional Ownership (41/100) is the weakest area to weigh before deciding. Notably: Low return on equity (8.45%). FII holding has been falling.

TopFund Score — Fundamentals Quality

67/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

62

Valuation

44

Cash Flow

75

Corporate Governance

86

Momentum

72

Institutional Ownership

41

Business Quality

57

Risk & Volatility

83

Liquidity

52

From Screener.in

  • +Company is almost debt free.
  • −Stock is trading at 3.22 times its book value
  • −The company has delivered a poor sales growth of 9.87% over past five years.
  • −Company has a low return on equity of 9.89% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Akums will attend Avendus Spark INDX investor conference on 16 November 2026 in Mumbai.

Transcript of the Earning/Quarterly Conference Call on the unaudited financial results for the quarter and half year ended on September 30, 2026

Audio recording of Q2 FY27 earnings call released for September 30, 2026 results.

CRISIL final report confirms Akums fully utilized 100% IPO proceeds for quarter ended September 30, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 1,181 1,083 944 1,019 1,033 1,010 1,056 1,024 1,018 1,160 1,158 1,167 1,342
Expenses + 1,029 989 941 891 912 889 962 895 923 1,013 1,006 992 1,148
Operating Profit 152 93 3 128 121 121 94 129 94 147 152 175 195
OPM % 13.0% 9.0% 0.3% 13.0% 12.0% 12.0% 9.0% 13.0% 9.0% 13.0% 13.0% 15.0% 15.0%
Other Income + -21 10 10 7 17 19 26 27 32 16 34 30 29
Interest 14 12 12 13 12 5 5 23 23 24 24 25 26
Depreciation 30 32 34 34 35 45 40 37 38 40 40 41 43
Profit before tax 87 59 -33 87 92 91 75 96 66 100 121 139 155
Tax % 62.0% -229.0% 20.0% 30.0% 27.0% 27.0% -99.0% 32.0% 35.0% 32.0% 33.0% 27.0% 26.0%
Net Profit + 33 195 -39 61 67 66 150 65 43 68 81 101 115
EPS in Rs 2 13 -3 4 4 4 9 4 3 4 5 6 7
Raw PDF — — — — — — — — — — — — —
YoY Sales growth — — — 5 -13 -7 12 0 -2 15 10 14 32

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 1,464 1,651 2,414 2,723 3,672 3,655 4,178 4,118 4,359 4,826
Expenses + 1,340 1,507 2,240 2,485 3,761 3,361 4,055 3,654 3,837 4,158
Operating Profit 124 144 174 238 -89 294 123 465 522 668
OPM % 8.0% 9.0% 7.0% 9.0% -2.4% 8.0% 3.0% 11.0% 12.0% 14.0%
Other Income + 6 6 26 11 7 15 8 69 108 109
Interest 23 22 20 7 17 46 51 35 94 98
Depreciation 31 38 67 70 95 113 126 153 155 164
Profit before tax 77 89 114 172 -193 150 -45 345 382 515
Tax % 51.0% 50.0% 62.0% 28.0% 30.0% 35.0% -102.0% 0.0% 33.0% —
Net Profit + 43 61 44 123 -251 98 1 344 256 365
EPS in Rs 3 4 3 8 -17 6 0 21 16 23
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 18.0% —
Sales growth — 13 — 13 35 0 14 -1 6 18

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 493 628 721 884 608 689 681 3,016 3,283 3,472
Borrowings + 255 213 175 130 395 619 565 88 157 117
Other Liabilities + 293 318 1,140 1,137 2,033 1,905 2,229 960 1,958 2,212
Total Liabilities 1,042 1,161 2,037 2,152 3,050 3,241 3,504 4,095 5,429 5,832
Fixed Assets + 444 501 645 904 1,021 1,097 1,191 1,397 1,456 1,536
CWIP 0 11 57 17 31 103 195 163 177 246
Investments 0 18 6 20 0 0 0 0 0 71
Other Assets + 598 632 1,329 1,212 1,998 2,041 2,118 2,535 3,796 3,979
Total Assets 1,042 1,161 2,037 2,152 3,050 3,241 3,504 4,095 5,429 5,832
Equity Capital 1 1 1 1 14 29 29 31 31 31

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 72 89 28 131 32 177 498 465 1,181
Cash from Investing Activity + -150 -123 -190 -109 -235 -305 -331 -548 -930
Cash from Financing Activity + 66 37 233 -91 236 125 -108 73 34
Net Cash Flow -11 4 71 -70 33 -4 59 -10 285
Free Cash Flow -78 -34 -34 49 -224 -110 212 201 958
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 72 98 44 74 -98 93 455 118 243

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 75.26% → 75.26%
  Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Others 2.73% 2.73% 2.73% 2.73% 2.73% 2.73% 2.73% 2.73% 2.73%
Public 7.14% 8.64% 8.84% 8.92% 10.46% 6.45% 6.29% 6.67% 6.42%
Promoters 75.26% 75.26% 75.26% 75.26% 75.26% 75.26% 75.26% 75.26% 75.26%
FII 7.34% 6.36% 5.77% 4.24% 2.27% 1.14% 1.38% 1.91% 4.5%
DII 7.53% 6.99% 7.39% 8.85% 9.28% 14.41% 14.36% 13.44% 11.09%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Akums Drugs And Pharma L (this stock) 11,279 29.9 3.22 8.45%
Viyash Scientific Limited 11,285 46.6 3.56 7.39%
Park Medi World Limited 11,039 43.1 5.12 16.8%
Metropolis Healthcare Ltd 11,711 50.7 7.13 13.6%
Concord Biotech Limited 12,146 42.6 5.86 12.9%
Symbiotec Pharmalab Ltd 10,354 70.0 7.6 11.7%
Yatharth Hosp & Tra C S L 10,222 53.6 5.44 10.2%

Which Mutual Funds Hold Akums Drugs And Pharma L?

Frequently Asked Questions about Akums Drugs And Pharma L

Community Sentiment

What are other investors saying about Akums Drugs And Pharma L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.